

**EFFECTIVE DATE:** 10|01|2019  
**POLICY LAST REVIEWED:** 06/03/2026

## OVERVIEW

Pulsed electrical and electromagnetic stimulation are being investigated to improve functional status and relieve pain related to osteoarthritis and rheumatoid arthritis that is unresponsive to other standard therapies. Electrical stimulation is provided using a device that noninvasively delivers a subsensory, low-voltage, monophasic electrical field to the target site of pain. Pulsed electromagnetic fields are delivered using coils placed over the skin.

## MEDICAL CRITERIA

Not applicable

## PRIOR AUTHORIZATION

Not applicable

## POLICY STATEMENT

### Medicare Advantage Plans

Electrical or electromagnetic stimulation for the treatment of osteoarthritis or any other condition is not covered as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Commercial Products

Electrical or electromagnetic stimulation for the treatment of osteoarthritis or any other condition is not medically necessary as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

## BACKGROUND

Electrical and electromagnetic stimulation are being investigated to improve functional status and to relieve pain related to osteoarthritis and rheumatoid arthritis that are unresponsive to other standard therapies. Noninvasive electrical stimulators generate a weak electrical current within the target site using pulsed electromagnetic fields, capacitive coupling, or combined magnetic fields. In capacitive coupling, small skin pads or electrodes are placed on either side of the knee or wrist. Electrical stimulation is provided by an electronic device that noninvasively delivers a subsensory low-voltage, monophasic electrical field to the target site of pain. Pulsed electromagnetic fields are delivered via treatment coils placed over the skin. Combined magnetic fields deliver a time-varying field by superimposing that field onto an additional static magnetic field.

In basic research studies, pulsed electrical stimulation has been shown to alter chondrocyte-related gene expression in vitro and to have regenerative effects in animal models of cartilage injury. It is proposed that the device treats the underlying cause of the disease by stimulating the joint tissue and improving the overall health of the joint and that it provides a slow-acting, but longer-lasting improvement in symptoms. Therefore, pulsed electrical stimulation is proposed to be similar to bone stimulator therapy for fracture nonunion.

The BioniCare Bio-1000™ stimulator (VQ OrthoCare) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process in 1997 to deliver pulsed electrical stimulation for adjunctive treatment of osteoarthritis of the knee, then later for rheumatoid arthritis of the hand. The FDA originally determined that this device was substantially equivalent to transcutaneous electrical nerve stimulation (TENS) devices. The manufacturer requested reclassification due to the fact that the target tissue is joint tissue, not nerve. In 2006, the FDA reclassified the device as a transcutaneous electrical stimulator for arthritis. The BioniCare System consists of an electronic stimulator device with electrical leads placed over the affected area and held in place with a lightweight, flexible wrap, and self-adhesive fasteners. The battery-powered device delivers small pulsed electrical currents of 0.0- to 12.0-V output. The device is currently marketed as the BioniCare Knee System.

The OrthoCor™ Active Knee System (OrthoCor Medical) uses pulsed electromagnetic field energy at a radiofrequency of 27.12 MHz to treat pain. In 2009, the OrthoCor Knee System was cleared for marketing by FDA through the 510(k) process and is classified as a short-wave diathermy device for use other than applying therapeutic deep heat (K091996, K092044). It is indicated for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue and for the treatment of muscle and joint aches and pain associated with overexertion, strains, sprains, and arthritis. The system includes single-use packs (pods) that deliver hot or cold. The predicate devices are the OrthoCor (K091640) and Ivivi Torino II™ (K070541).

In 2008, the SofPulse™ (also called Torino II, 912-M10, and Roma3™; Ivivi Health Sciences, renamed Amp Orthopedics) was cleared for marketing by the FDA through the 510(k) process as a short-wave diathermy device that applies electromagnetic energy at a radiofrequency of 27.12 MHz (K070541). The device is indicated for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue.

In 2017, the ActiPatch® (BioElectronics) was cleared for marketing by the FDA through the 510(k) process for nonprescription use for adjunctive treatment of plantar fasciitis of the heel and osteoarthritis of the knee (K152432). In January 2020, the ActiPatch indications for use were broadened to adjunctive treatment of musculoskeletal pain.

With the exception of ActiPatch, nonprescription devices are not evaluated in this review.

For individuals who have arthritis who receive pulsed electrical or electromagnetic stimulation, the evidence includes systematic reviews and a number of small randomized controlled trials (RCTs). Relevant outcomes are symptoms, functional outcomes, health status measures, and treatment-related morbidity. A review of the literature did not find adequate evidence that use of pulsed electrical or electromagnetic stimulation for the treatment of arthritis improves health outcomes. A 2020 meta-analysis identified 15 randomized sham-controlled trials on treatment of osteoarthritis of the knee. There was some evidence of clinically and statistically significant improvement in pain, but no evidence of clinically significant improvement in stiffness, function, or quality of life. These conclusions are limited by methodologic shortcomings and inconsistent trial results. Variable results seen in more recent RCTs might also be related to the different devices and treatment durations used. Additional studies with larger numbers of subjects are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## **CODING**

There is no specific CPT code for electrical or electromagnetic stimulation for the treatment of arthritis.

If the following code is filed for the services in this policy, the claim will be denied as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

**E0762** Transcutaneous electrical joint stimulation device system, includes all accessories

## RELATED POLICIES

Electrical Stimulation and Electromagnetic Therapy for Wound Treatment

## PUBLISHED

Provider Update, August 2026  
Provider Update, May 2025  
Provider Update, May 2024  
Provider Update, July 2023  
Provider Update, September 2022

## REFERENCES

1. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD), Transcutaneous Electrical Joint Stimulation Devices (TEJSD) (L34821)
2. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD) Article, Transcutaneous Electrical Joint Stimulation Devices (TEJSD) – Policy Article (A52713)
3. Department of Health & Human Services. Correction to substantially equivalent letter of June 6, 2003 for BionicCare Stimulator. June 8, 2006. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf3/K030332.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf3/K030332.pdf). Accessed January 12, 2026.
4. Yang X, He H, Ye W, et al. Effects of Pulsed Electromagnetic Field Therapy on Pain, Stiffness, Physical Function, and Quality of Life in Patients With Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *Phys Ther*. Jul 19 2020; 100(7): 1118-1131. PMID 32251502
5. Negm A, Lorbergs A, Macintyre NJ. Efficacy of low frequency pulsed subsensory threshold electrical stimulation vs placebo on pain and physical function in people with knee osteoarthritis: systematic review with meta-analysis. *Osteoarthritis Cartilage*. Sep 2013; 21(9): 1281-9. PMID 23973142
6. Fary RE, Carroll GJ, Briffa TG, et al. The effectiveness of pulsed electrical stimulation in the management of osteoarthritis of the knee: results of a double-blind, randomized, placebo-controlled, repeated-measures trial. *Arthritis Rheum*. May 2011; 63(5): 1333-42. PMID 21312188
7. Li S, Yu B, Zhou D, et al. Electromagnetic fields for treating osteoarthritis. *Cochrane Database Syst Rev*. Dec 14 2013; (12): CD003523. PMID 24338431
8. Garland D, Holt P, Harrington JT, et al. A 3-month, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a highly optimized, capacitively coupled, pulsed electrical stimulator in patients with osteoarthritis of the knee. *Osteoarthritis Cartilage*. Jun 2007; 15(6): 630-7. PMID 17303443
9. Zizic TM, Hoffman KC, Holt PA, et al. The treatment of osteoarthritis of the knee with pulsed electrical stimulation. *J Rheumatol*. Sep 1995; 22(9): 1757-61. PMID 8523357
10. Bagnato GL, Miceli G, Marino N, et al. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo controlled, randomized clinical trial. *Rheumatology (Oxford)*. Apr 2016; 55(4): 755-62. PMID 26705327
11. Wuschech H, von Hehn U, Mikus E, et al. Effects of PEMF on patients with osteoarthritis: Results of a prospective, placebo-controlled, double-blind study. *Bioelectromagnetics*. Dec 2015; 36(8): 576-85. PMID 26562074
12. Nelson FR, Zvirbulis R, Pilla AA. Non-invasive electromagnetic field therapy produces rapid and substantial pain reduction in early knee osteoarthritis: a randomized double-blind pilot study. *Rheumatol Int*. Aug 2013; 33(8): 2169-73. PMID 22451021
13. Fukuda TY, Alves da Cunha R, Fukuda VO, et al. Pulsed shortwave treatment in women with knee osteoarthritis: a multicenter, randomized, placebo-controlled clinical trial. *Phys Ther*. Jul 2011; 91(7): 1009-17. PMID 21642511
14. Dundar U, Asik G, Ulasli AM, et al. Assessment of pulsed electromagnetic field therapy with Serum YKL-40 and ultrasonography in patients with knee osteoarthritis. *Int J Rheum Dis*. Mar 2016; 19(3): 287-93. PMID 25955771
15. Ozguclu E, Cetin A, Cetin M, et al. Additional effect of pulsed electromagnetic field therapy on knee osteoarthritis treatment: a randomized, placebo-controlled study. *Clin Rheumatol*. Aug 2010; 29(8): 927-31. PMID 20473540
16. Trock DH, Bollet AJ, Dyer RH, et al. A double-blind trial of the clinical effects of pulsed electromagnetic fields in osteoarthritis. *J Rheumatol*. Mar 1993; 20(3): 456-60. PMID 8478852

17. Trock DH, Bollet AJ, Markoll R. The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials. *J Rheumatol.* Oct 1994; 21(10): 1903-11. PMID 7837158
18. Jacobson JI, Gorman R, Yamanashi WS, et al. Low-amplitude, extremely low frequency magnetic fields for the treatment of osteoarthritic knees: a double-blind clinical study. *Altern Ther Health Med.* Sep-Oct 2001; 7(5): 54-64, 66-9. PMID 11565402
19. Pipitone N, Scott DL. Magnetic pulse treatment for knee osteoarthritis: a randomised, double-blind, placebo controlled study. *Curr Med Res Opin.* 2001; 17(3): 190-6. PMID 11900312
20. Thamsborg G, Florescu A, Oturai P, et al. Treatment of knee osteoarthritis with pulsed electromagnetic fields: a randomized, double-blind, placebo-controlled study. *Osteoarthritis Cartilage.* Jul 2005; 13(7): 575-81. PMID 15979009
21. Sutbeyaz ST, Sezer N, Koseoglu BF. The effect of pulsed electromagnetic fields in the treatment of cervical osteoarthritis: a randomized, double-blind, sham-controlled trial. *Rheumatol Int.* Feb 2006; 26(4): 320-4. PMID 15986086
22. Ay S, Evcik D. The effects of pulsed electromagnetic fields in the treatment of knee osteoarthritis: a randomized, placebo-controlled trial. *Rheumatol Int.* Apr 2009; 29(6): 663-6. PMID 19015858
23. Kulcu DG, Gulsen G, Altunok EC. Short-term efficacy of pulsed electromagnetic field therapy on pain and functional level in knee osteoarthritis: a randomized clinical study. *Turk J Rheumatol.* 2009;24(3):144-148.
24. Moldovan I, Dita R, Pop L. The effects of focused pulsed electromagnetic field therapy in patients with knee osteoarthritis. A randomized, placebo-controlled study. *Palestrica of the Third Millenium Civilization and Sport.* 2012;13:91-95.
25. Pavlovic AS, Djurasic LM. The effect of low frequency pulsing electromagnetic field in treatment of patients with knee joint osteoarthritis. *Acta Chir Jugosl.* 2012; 59(3): 81-3. PMID 23654012
26. Kanat E, Alp A, Yurtkuran M. Magnetotherapy in hand osteoarthritis: a pilot trial. *Complement Ther Med.* Dec 2013; 21(6): 603-8. PMID 24280467
27. Nicolakis P, Kollmitzer J, Crevenna R, et al. Pulsed magnetic field therapy for osteoarthritis of the knee--a double-blind sham-controlled trial. *Wien Klin Wochenschr.* Aug 30 2002; 114(15-16): 678-84. PMID 12602111
28. Tong J, Chen Z, Sun G, et al. The Efficacy of Pulsed Electromagnetic Fields on Pain, Stiffness, and Physical Function in Osteoarthritis: A Systematic Review and Meta-Analysis. *Pain Res Manag.* 2022; 2022: 9939891. PMID 35586276
29. Durtschi MS, Rajakumar V, Kenney DE, et al. Clinical Efficacy of Pulsed Electromagnetic Field Therapy on Thumb Carpometacarpal Joint Pain: A Double-Blind, Randomized, Controlled Trial. *Hand (N Y).* Sep 28 2025: 15589447251371088. PMID 41015912
30. Wang QW, Ong MT, Man GC, et al. The effects of pulsed electromagnetic field therapy on muscle strength and pain in patients with end-stage knee osteoarthritis: a randomized controlled trial. *Front Med (Lausanne).* 2024; 11: 1435277. PMID 39478814
31. Yabroudi MA, Aldardour A, Nawasreh ZH, et al. Effects of the combination of pulsed electromagnetic field with progressive resistance exercise on knee osteoarthritis: A randomized controlled trial. *J Back Musculoskelet Rehabil.* 2024; 37(1): 55-65. PMID 37718773
32. de Paula Gomes CAF, Politti F, de Souza Bacelar Pereira C, et al. Exercise program combined with electrophysical modalities in subjects with knee osteoarthritis: a randomised, placebo-controlled clinical trial. *BMC Musculoskelet Disord.* Apr 20 2020; 21(1): 258. PMID 32312265
33. Hackel JG, Paci JM, Gupta S, et al. Evaluating Noninvasive Pulsed Electromagnetic Field Therapy for Joint and Soft Tissue Pain Management: A Prospective, Multi-center, Randomized Clinical Trial. *Pain Ther.* Apr 2025; 14(2): 723-735. PMID 39928254
34. American Academy of Orthopaedic Surgeons. Management of osteoarthritis of the knee (non-arthroplasty). 2021; <https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-knee/oak3cpg.pdf>. Accessed January 12, 2026.
35. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care Res (Hoboken).* Feb 2020; 72(2): 149-162. PMID 31908149

36. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. Jul 2021; 73(7): 924-939. PMID 34101387
37. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage*. Nov 2019; 27(11): 1578-1589. PMID 31278997.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

